Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Pharmacokinetics

    Current Location

    Search
    Pharmacokinetics
    Show Map
    Map View
    Your Location
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      77 Pharmacokinetics Trials Near You

      Power is an online platform that helps thousands of Pharmacokinetics patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      CSL889 for Sickle Cell Disease During Pain Crisis

      Columbus, Ohio
      This study consists of two parts: phase 2 (Part A) and phase 3 (Part B). It is a multicenter study designed to evaluate the safety, effectiveness, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD, and to evaluate the safety and tolerability of CSL889 in study participants.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2, 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Frequent VOCs, ACS, Stroke, AKI, Others
      Must Not Be Taking:Methadone, Buprenorphine

      260 Participants Needed

      Belimumab + Rituximab for Kidney Disease

      Columbus, Ohio
      The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy. Background: Primary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages and races. The peak incidence of MN is in the fifth decade of life. Primary MN is recognized to be an autoimmune disease, a disease where the body's own immune system causes damage to kidneys. This damage can cause the loss of too much protein in the urine. Drugs used to treat MN aim to reduce the attack by one's own immune system on the kidneys by blocking inflammation and reducing the immune system's function. These drugs can have serious side effects and often do not cure the disease. There is a need for new treatments for MN that are better at improving the disease while reducing fewer treatment associated side effects. In this study, researchers will evaluate if treatment with a combination of two different drugs, belimumab and rituximab, is effective at blocking the immune attacks on the kidney compared to rituximab alone. Rituximab works by decreasing a type of immune cell, called B cells. B cells are known to have a role in MN. Once these cells are removed, disease may become less active or even inactive. However, after stopping treatment, the body will make new B cells which may cause disease to become active again. Belimumab works by decreasing the new B cells produced by the body and, may even change the type of new B cells subsequently produced. Belimumab is approved by the US Food and Drug Administration (FDA) to treat systemic lupus erythematosus (also referred to as lupus or SLE). Rituximab is approved by the FDA to treat some types of cancer, rheumatoid arthritis, and vasculitis. Neither rituximab nor belimumab is approved by the FDA to treat MN. Treatment with a combination of belimumab and rituximab has not been studied in individuals with MN, but has been tested in other autoimmune diseases, including lupus nephritis and Sjögren's syndrome.
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Secondary MN, Poor Diabetes Control, HIV, Others
      Must Be Taking:RAS Blockers

      58 Participants Needed

      Intravesical Enfortumab Vedotin for Bladder Cancer

      Columbus, Ohio
      This trial tests a new treatment for bladder cancer by delivering the drug directly into the bladder through a thin tube. The study will determine the best dose and evaluate its effectiveness and side effects.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Muscle-invasive Cancer, Metastatic Disease, Others
      Must Not Be Taking:Chemotherapy, Immunotherapy, Others

      58 Participants Needed

      CC-220 Combination Therapy for Multiple Myeloma

      Columbus, Ohio
      This trial tests a new drug, CC-220, alone and with other drugs for patients with multiple myeloma who haven't responded to other treatments or are newly diagnosed. The drugs work by controlling cancer cell growth and killing cancer cells through different mechanisms.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Nonsecretory Multiple Myeloma, Other Malignancies, Others

      466 Participants Needed

      Buprenorphine for Opioid Addiction during Pregnancy

      Cincinnati, Ohio
      This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1). Participants in MOMs will be offered the opportunity to enroll in this sub-study, which is designed to evaluate conceptual models of the mechanisms by which extended-release buprenorphine (BUP-XR), may improve mother-infant outcomes, compared to sublingual buprenorphine (BUP-SL). The additional data collected in this sub-study will be combined with data from the main MOMs trial. It is hypothesized that: (1) the buprenorphine blood levels will vary, depending on which formulation of buprenorphine was received, (2) the variation in buprenorphine blood levels will be associated with fetal behavior (including fetal heart rate variability) (3) the variation in buprenorphine blood levels will be associated with differences in mother outcomes (including medication adherence and illicit opioid use) (4) the variation in buprenorphine blood levels and in fetal behavior will be associated with infant outcomes (including neonatal opioid withdrawal syndrome and infant development).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 41
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      97 Participants Needed

      Belimumab for Lupus

      Cincinnati, Ohio
      This trial is testing a medication called belimumab, given as an injection under the skin, in children with lupus. The goal is to see if it is safe and effective by calming down their overactive immune systems. Belimumab is approved for the treatment of lupus in adults with moderate disease activity.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Severe Nephritis, Organ Transplant, Malignancy, Others
      Must Be Taking:Corticosteroids, Immunosuppressives, Anti-malarials, NSAIDs

      25 Participants Needed

      GSK3882347 for Urinary Tract Infection (UTI)

      Cincinnati, Ohio
      This trial tests a new medication, GSK3882347, to treat urinary tract infections in adult women. The study will see if the medication can effectively clear the infection and check for any side effects. Participants will take the medication for a short period, and researchers will compare it to an existing treatment to ensure accurate results.

      Trial Details

      Trial Status:Recruiting
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      122 Participants Needed

      ROSE-010 for Obesity

      Cincinnati, Ohio
      The primary objective of this study is to assess the efficacy of ROSE-010 on food intake in female subjects with overweight and obesity. The secondary objectives of this study are the following: * To assess the efficacy of ROSE-010 on hunger; * To assess the efficacy of ROSE-010 on satiety; * To assess the efficacy of ROSE-010 on prospective consumption; * To assess the efficacy of ROSE-010 on desire to eat; * To assess the efficacy of ROSE-010 on palatability; * To characterize the pharmacokinetics (PK) of ROSE-010 following subcutaneous (SC) administration on Day 1 and Day 7; and * To evaluate safety and tolerability of SC administrations of ROSE-010 to overweight and obese subjects.

      Trial Details

      Trial Status:Not Yet Recruiting
      Age:18 - 65
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      40 Participants Needed

      Hydroxyurea for Sickle Cell Anemia

      Cincinnati, Ohio
      This trial studies how to best use hydroxyurea, a medication that helps blood cells stay round and flexible, in children with sickle cell anemia. It aims to find the right dose for each child and monitor their health. The study also looks at ways to check if children are taking their medication regularly. Hydroxyurea has been used for over 25 years to treat sickle cell anemia, showing efficacy in both adults and children.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:6 - 21

      Key Eligibility Criteria

      Disqualifiers:Family Unwillingness
      Must Be Taking:Hydroxyurea

      150 Participants Needed

      AZD6244 for Neurofibromatosis

      Cincinnati, Ohio
      Background: \- Plexiform neurofibromas are tumors that grow in and around nerves. The only way to treat them is with surgery. Some of these tumors cannot be completely removed. The tumors may be too large, too numerous, or in a bad location for surgery. An experimental drug called AZD6244 hydrogen sulfate may be able to prevent the tumors from growing, slow down their growth, or shrink them. This drug has been tested in adults with cancer and in children with some types of brain cancer. This study will test how well this drug works with these types of tumors. Objectives: \- To study the safety and effectiveness of AZD6244 hydrogen sulfate in children and young adults with plexiform neurofibromas that cannot be completely removed by surgery. Eligibility: \- Children and young adults between 12 and 18 years of age who have plexiform neurofibromas that cannot be completely removed by surgery. Design: * Patients will be screened with a physical exam, medical history, blood tests, and imaging studies. * They will take the study drug twice a day with 8 ounces of water, every day for 28-day cycles of treatment. During study visits, participants will have blood and urine tests and physical exams. They will also have imaging studies to examine the tumor sizes and locations. They will answer questions about their health. They may have other tests as needed. * Participants will continue to receive the study drug as long as they have no severe side effects and the disease is not getting worse.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:2 - 18

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Severe Disease, HIV, Others
      Must Not Be Taking:Antiretrovirals, Vitamin E

      99 Participants Needed

      BMS-986435 for Heart Failure

      Cincinnati, Ohio
      This trial is testing a new drug called BMS-986435/MYK-224 in people with a specific type of heart failure (HFpEF). The goal is to see if the drug is safe and if it can help improve heart function and reduce symptoms.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:40 - 85

      Key Eligibility Criteria

      Disqualifiers:Obstructive Cardiomyopathy, Cardiac Amyloidosis, Others

      208 Participants Needed

      Secukinumab for Giant Cell Arteritis and Polymyalgia Rheumatica

      Cincinnati, Ohio
      This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics \[PK\]) and whether it will be safe and tolerable after multiple doses of i.v. Secukinumab infusion in adult patients with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:50 - 100

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      65 Participants Needed

      Belimumab for Pediatric Lupus

      Cincinnati, Ohio
      This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic lupus erythematosus
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Severe Lupus Kidney, Others
      Must Not Be Taking:Belimumab, B Cell Therapy

      93 Participants Needed

      Mevrometostat + Enzalutamide for Prostate Cancer

      Cincinnati, Ohio
      This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, Brain Metastasis, Others
      Must Be Taking:Enzalutamide

      1000 Participants Needed

      Pepinemab + Pembrolizumab for Head and Neck Cancer

      Canton, Ohio
      The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      65 Participants Needed

      Buprenorphine for Opioid Use Disorder in Pregnancy

      Huntington, West Virginia
      This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1). Caretakers of the infants delivered by MOMs participants will be offered the opportunity to enroll in this sub-study, which is designed to evaluate the impact of extended-release buprenorphine (BUP-XR), relative to sublingual buprenorphine (BUP-SL), on infant neurodevelopment. The additional data collected in this sub-study will be combined with data from the main MOMs trial.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      200 Participants Needed

      Eltrombopag for Aplastic Anemia

      Cleveland, Ohio
      This is a phase II, open label, multi-center, intra-patient dose escalation study to characterize the pharmacokinetics (PK) after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric patients with previously untreated or relapsed/refractory severe aplastic anemia or recurrent aplastic anemia.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:1 - 18

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      51 Participants Needed

      Etrasimod for Ulcerative Colitis

      Cleveland, Ohio
      This trial is testing etrasimod, a medication aimed at treating severe ulcerative colitis in adolescents aged 12 to 17. The drug works by calming the immune system to reduce inflammation in the colon. Participants will be treated for up to a year, with an option to continue for several more years. Etrasimod is an oral medication designed to help with inflammatory conditions.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Severe Colitis, Crohn's, Others

      36 Participants Needed

      Venetoclax + Dexamethasone vs Pomalidomide + Dexamethasone for Multiple Myeloma

      Cleveland, Ohio
      A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Other Malignancies, GvHD, CNS Involvement, Others
      Must Not Be Taking:BCL-2 Inhibitors, Pomalidomide

      265 Participants Needed

      High-Dose Ocrelizumab for Multiple Sclerosis

      Cleveland, Ohio
      This trial is testing if a higher dose of ocrelizumab given through an IV drip is more effective and safe for patients with Primary Progressive Multiple Sclerosis (PPMS). The drug works by reducing harmful immune cells to potentially slow down the disease. Ocrelizumab is the first drug approved for treating both relapsing and primary progressive forms of multiple sclerosis.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Cancer, Immunocompromised, Infections, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids, CD20s, Others

      769 Participants Needed

      Why Other Patients Applied

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51
      Match to a Pharmacokinetics Trial

      Lapatinib + Trastuzumab for HER2 Positive Breast Cancer

      Cleveland, Ohio
      This phase II trial studies the side effects and how well lapatinib ditosylate and trastuzumab work in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other parts of the body (metastatic). Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or tumor cancer-killing substances to them. Giving lapatinib ditosylate together with trastuzumab may kill more tumor cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Cardiac Disease, Infection, Others
      Must Not Be Taking:CYP3A4 Inhibitors/inducers

      40 Participants Needed

      AB521 for Renal Cell Carcinoma

      Cleveland, Ohio
      This trial is testing a new drug called AB521 to see if it is safe for people with advanced cancers, including a type of kidney cancer called clear cell renal cell carcinoma. In some parts of the study, AB521 will be used alone, and in others, it will be combined with another drug called cabozantinib, which stops cancer cells from growing.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiac, Respiratory, Psychiatric, Others
      Must Not Be Taking:HIF-2α Inhibitors, Cabozantinib

      302 Participants Needed

      ASP3082 for Cancer

      Cleveland, Ohio
      This trial is testing a new drug called ASP3082 for adults with advanced cancers. The drug works by blocking harmful proteins. The study will determine the best dose and check for any side effects.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Active Hepatitis, HIV, Others
      Must Not Be Taking:KRAS Inhibitors

      651 Participants Needed

      ASP1002 for Cancer

      Cleveland, Ohio
      This trial is testing ASP1002, a new medicine for certain cancers. It focuses on adults with advanced tumors that haven't responded to other treatments. Researchers aim to understand how the body processes ASP1002 and its side effects, to find the best dose for future use.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Autoimmune Disease, Cardiac Disease, Others
      Must Not Be Taking:Immunosuppressants, Steroids

      210 Participants Needed

      Telavancin for Subarachnoid Hemorrhage

      Lexington, Kentucky
      The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs) in patients who have had spontaneous subarachnoid hemorrhage (SAH). Patients with SAH were chosen as the target population because they frequently require prolonged admission to the intensive care unit and drainage of CSF in order to prevent hydrocephalus. The estimated sample size is 20 subjects. This is a prospective cohort of patients with SAH. Patients will be included if they have a spontaneous SAH, aged 18-65 years old, Hunt-Hess score of 1-4 \& has an actively draining ventriculostomy. Subjects will receive telavancin 10mg/kg (maximum 1000mg) every 24 hours for 3 consecutive doses. Serial serum and CSF samples will be obtained. An 8-hour urine collection will be completed on study day 2 in order to define the patient's measured creatinine clearance.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Hypersensitivity To Telavancin, Reduced Renal Function, Severe Anemia, Others

      20 Participants Needed

      Cefazolin Dosing for Surgical Prophylaxis

      Ann Arbor, Michigan
      The goal of this clinical study is to compare the dosing of an antibiotic in overweight patients having surgery. The main question\[s\] it aims to answer are: * Are the antibiotic concentrations in blood and fat tissue in patients that are overweight sufficient to prevent the chance of infection? * Can dosing using body composition rather than body weight improve the chance of achieving good antibiotic concentrations in overweight patients? Participants will allow us to collect small amounts of blood and fat tissue during their regularly scheduled surgery. Researchers will compare differences in antibiotic concentrations based on dosing by standard of care (body weight based) versus body composition.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Penicillin Allergy, Pregnancy
      Must Be Taking:Cefazolin

      104 Participants Needed

      Nilotinib + Dabrafenib/Trametinib for Melanoma

      Lexington, Kentucky
      This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresectable melanoma carrying a BRAF V600 mutation and have relapsed on a BRAF/MEK inhibitor therapy. The goal is to assess the toxicity and tolerability and determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of the combination of nilotinib with dabrafenib and trametinib or with encorafenib and binimetinib. Additionally, this study will assess pharmacokinetic parameters of dabrafenib and nilotinib when used in combination.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Chronic Hypokalemia, Long QT Syndrome, Others
      Must Be Taking:BRAF/MEK Inhibitors

      30 Participants Needed

      Chemotherapy Dosing Strategies for Peritoneal Carcinomatosis

      Lexington, Kentucky
      Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically been associated with poor overall survival (≤ 12 months) with few treatment options. Cytoreductive surgery (CRS), which involves removal of all macroscopic tumor nodules, combined with direct administration of heated intra-peritoneal (IP) chemotherapy (HIPEC) to the affected peritoneal surfaces, has been shown to be an effective treatment option that extends overall survival among certain cases of peritoneal carcinomatosis. IP chemotherapy allows delivery of a high dose of cytostatic drug directly onto the peritoneal surfaces at risk for microscopic residual disease while systemic exposure remains limited. Additionally, hyperthermia is known to enhance the cytotoxicity of several agents (including Mitomycin C) and improves the depth of peritoneal penetration. This trial will be a randomized phase 2 comparison of flat dose versus weight-based dose Mitomycin C. The hypothesis of this study is that HIPEC weight-based dosing may result in similarly effective peritoneal Mitomycin C concentrations with less systemic absorption and potential systemic toxicity, compared with the HIPEC flat dosing approach in patients undergoing CRS/HIPEC.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Extra-abdominal Metastases, Brain Metastases, Others
      Must Not Be Taking:Investigational Agents

      100 Participants Needed

      Vancomycin for Obesity

      Ann Arbor, Michigan
      The goal of this clinical trial is to learn how to optimize vancomycin dosing in obese adults based on weight and kidney function. It will also assess the safety of different vancomycin dosing strategies. The main questions it aims to answer are: Does dosing vancomycin based on kidney function provide better drug exposure than dosing based on weight? What medical or safety issues arise when vancomycin is dosed according to weight versus kidney function? Participants will be randomized into two groups. One group will receive vancomycin doses based on their weight, while the other will receive doses based on their kidney function. Participants will: Receive a single dose of vancomycin based on either their weight or kidney function after pretreatment with antihistamines Provide blood and urine samples at specific times for pharmacokinetic analysis Undergo body composition measurements using DEXA scans and other methods Visit the clinic for physical exams, medical history, and laboratory tests
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Allergies, Cardiovascular, Renal, Others
      Must Not Be Taking:GLP1 Agonists, Ototoxic Drugs

      24 Participants Needed

      Paclitaxel for Breast Cancer

      Ann Arbor, Michigan
      The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Hypersensitivity To Paclitaxel, Pregnant, Others
      Must Not Be Taking:CYP2C8 Inducers, Inhibitors

      22 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Adenoid Cystic Carcinoma Clinical Trials

      Top Clinical Trials near Brisbane, CA

      Top Colorectal Cancer Clinical Trials near Kansas City, MO

      Top Flu Clinical Trials

      Top Prevention Clinical Trials

      Top Clinical Trials near Athens, GA

      Top Clinical Trials near Corona, CA

      Top Clinical Trials near Jackson, MI

      180 Clinical Trials near Ithaca, NY

      Top Covid Clinical Trials

      Top Clinical Trials near Edgewood, KY

      Top Eczema Clinical Trials near Phoenix, AZ

      By Trial

      Mindfulness for Postoperative Pain and Anxiety

      IV C1 Esterase Inhibitor for Hereditary Angioedema

      OK-101 for Neuropathic Corneal Pain

      BGB-16673 Combination for B-Cell Lymphoma

      MRI Scans for Low Grade Glioma

      Evorpacept for Advanced Cancers

      Neoadjuvant Cabozantinib for Kidney Cancer

      Bupivacaine for Kidney Stones

      JenaValve Pericardial TAVR System for Aortic Regurgitation

      Proton Therapy for Recurrent Head and Neck Cancer

      Amniotic Suspension Allograft for Knee Osteoarthritis

      Self-Affirmation for Diabetes

      Frequently Asked Questions

      How much do Pharmacokinetics clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Pharmacokinetics clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Pharmacokinetics trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Pharmacokinetics is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Pharmacokinetics medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Pharmacokinetics clinical trials?

      Most recently, we added MDMA for Liver Disease, Coenzyme Q10 Formulations for Pharmacokinetics Study and Methadone for Postoperative Pain to the Power online platform.